lobeglitazone: Clinical Trials

37 trials of lobeglitazone, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

28 completed, 8 unknown, 1 not yet recruiting. 27 Phase 1, 5 Phase 3, 4 Phase 4, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 127Completed 23, Unknown 4
Phase 35Completed 3, Unknown 2
Phase 44Unknown 2, Completed 1, Not yet recruiting 1
Phase 21Completed 1

Follow lobeglitazone: new trials by email Literature Review of lobeglitazone trials Research Report on lobeglitazone

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers
CKD-383 0.25/12.5/1000mg, CKD-501, D745, D150 - Type 2 Diabetes
Phase 1CompletedChong Kun Dang Pharmaceutical302025-10-302025-12-26
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers
CKD-383 0.5/10/1000mg, CKD-501, D744, D150 - Type 2 Diabetes
Phase 1CompletedChong Kun Dang Pharmaceutical302025-10-282025-12-26
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy Volunteers
CKD-383 0.5/25/1000mg, CKD-501, D745, D150 - Type 2 Diabetes
Phase 1CompletedChong Kun Dang Pharmaceutical312025-10-242025-12-26
Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors
Sitagliptin 100 mg, Sitagliptin 100 mg + Dapagliflozin 10 mg, Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg - Diabetes Mellitus, Type 2, Hyperglycemia
Phase 4Not yet recruitingYonsei University1002025-09-012025-08-07
To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy Volunteers
CKD-383(Fed), CKD-383(Fasted) - Type 2 Diabetes Mellitus
Phase 1UnknownChong Kun Dang Pharmaceutical282024-07-042024-07-10
Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029
CKD-383, CKD-501, D745, D150, D029 - Type 2 Diabetes
Phase 1CompletedChong Kun Dang Pharmaceutical302023-07-142024-01-23
Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150
CKD-383, CKD-501, D744, D150 - Type 2 Diabetes
Phase 1CompletedChong Kun Dang Pharmaceutical322023-05-262024-01-23
A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions
CKD-393(2), CKD-501, D759, D150, D029 - Type2Diabetes
Phase 1CompletedChong Kun Dang Pharmaceutical312022-04-212022-06-30
Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety
Dapagliflozin 10mg Tab, Lobeglitazone 0.5 mg, Dapagliflozin + Lobeglitazone - Diabetes Type 2
Phase 4UnknownSeoul National University Bundang Hospital992022-01-012023-08-14
Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393
CKD-393, CKD-501, D759, H053 - Type 2 Diabetes
Phase 1CompletedChong Kun Dang Pharmaceutical332021-11-252023-06-09
Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg
CKD-398, CKD-501, D745 - Type 2 Diabetes Mellitus
Phase 1CompletedChong Kun Dang Pharmaceutical322021-05-272021-08-25
A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383.
CKD-501, D745, D150, CKD-383 - Type2 Diabetes Mellitus
Phase 1CompletedChong Kun Dang Pharmaceutical272021-04-162021-06-10
Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393
CKD-501, D759, D150, CKD-393 0.5/100/1000 mg - T2DM (Type 2 Diabetes Mellitus)
Phase 1UnknownChong Kun Dang Pharmaceutical262021-02-182021-01-12
A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)
CKD 501, D759, D150, CKD-501, D759, D150 - Type 2 Diabetes Mellitus
Phase 1CompletedChong Kun Dang Pharmaceutical482020-06-152020-11-16
A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150
CKD-501, D745, D150, CKD-501, D745, D150 - Type 2 Diabetes
Phase 1CompletedChong Kun Dang Pharmaceutical482020-05-072020-10-30
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects
CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T, CKD-393 0.5/100/1000mg formulation 1 Tab. 1T, CKD-393 0.5/100/1000mg formulation 2 Tab. 1T - Diabetes Mellitus, Type 2
Phase 1CompletedChong Kun Dang Pharmaceutical242020-04-082021-04-30
A Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-396
CKD-501 and D759, CKD-396 - Type2 Diabetes Mellitus
Phase 1UnknownChong Kun Dang Pharmaceutical262020-02-242020-02-05
Clinical Trial to Evaluate the Drug Drug Interaction of CKD-501 and D308
D308, CKD-501 - Diabetes Mellitus, Type II
Phase 1CompletedChong Kun Dang Pharmaceutical412018-07-252018-11-19
The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 Diabetes
CKD-501 0.5mg, Placebo - Type2 Diabetes
Phase 3UnknownChong Kun Dang Pharmaceutical2402018-05-022018-08-22
Efficacy and Safety of CKD-501 Added to D150 Plus D745 25mg Therapy in Patients With Type 2 Diabetes
CKD-501 0.5mg, Placebo - Type2 Diabetes
Phase 3UnknownChong Kun Dang Pharmaceutical2402018-04-262018-08-13

Showing 20 of 37. Sign in to see all of them.

Conditions studied

Diabetes Mellitus, Type 2 (26)  ·  Hyperglycemia (1)  ·  Insulin Resistance (1)  ·  Liver Diseases (1)  ·  Renal Insufficiency (1)

Sponsors

Chong Kun Dang Pharmaceutical (33)  ·  Seoul National University Bundang Hospital (3)  ·  Yonsei University (1)

Countries

South Korea (34)

Top investigators

Anhye Kim, Ph.D (3)  ·  BongSoo Cha, Ph.D (2)  ·  Ji Young Park, Ph.D. (2)  ·  Min Gul Kim, M.D, Ph.D. (2)  ·  Min Soo Park, Ph.D. M.D (2)  ·  Min-Gul Kim, MD,PhD (2)  ·  Minsoo Park (2)  ·  Choon Ok Kim, M.D., Ph.D. (1)  ·  Choon Ok Kim, M.D., PhD. (1)  ·  Dongseop Choi (1)  ·  Dongseop Choi, MD.,Ph.D. (1)  ·  Jae Kuk Shin, Ph.D. M.D (1)  ·  Jae Wook Ko, Ph.D (1)

Results publications

PMID 32362346, PMID 22697273, PMID 24736628, PMID 25047497, PMID 26163202, PMID 31992459, PMID 33099742, PMID 33953542, PMID 37034122